Joanna Siuda1, Barbara Jasinska-Myga2, Magdalena Boczarska-Jedynak2, Grzegorz Opala2, Fabienne C Fiesel3, Elisabeth L Moussaud-Lamodière3, Leslie A Scarffe4, Valina L Dawson5, Owen A Ross3, Wolfdieter Springer3, Ted M Dawson6, Zbigniew K Wszolek7. 1. Department of Neurology, Silesian Medical University, Katowice, Poland; Department of Neuroscience, Mayo Clinic Jacksonville, Florida, USA. 2. Department of Neurology, Silesian Medical University, Katowice, Poland. 3. Department of Neuroscience, Mayo Clinic Jacksonville, Florida, USA. 4. Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns, Hopkins University School of Medicine, Baltimore, MD 21205, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. 5. Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns, Hopkins University School of Medicine, Baltimore, MD 21205, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA. 6. Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns, Hopkins University School of Medicine, Baltimore, MD 21205, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130-2685, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. 7. Department of Neurology, Mayo Clinic Jacksonville, Florida, USA. Electronic address: wszolek.zbigniew@mayo.edu.
Abstract
BACKGROUND: Recessive mutations in the PTEN-induced putative kinase 1 (PINK1) gene cause early-onset Parkinson's disease (EOPD). The clinical phenotype of families that have this PINK1-associated disease may present with different symptoms, including typical PD. The loss of the PINK1 protein may lead to mitochondrial dysfunction, which causes dopaminergic neuron death. METHODS: The clinical phenotypes of a large Polish family with EOPD and an identified PINK1 homozygous nonsense mutation were assessed. Ubiquitination and degradation of mitochondrial parkin substrates as well as mitochondrial bioenergetics were investigated as direct functional readouts for PINK1's kinase activity in biopsied dermal fibroblasts. RESULTS: A four-generation family was genealogically evaluated. Genetic screening identified two affected subjects who were both homozygous carriers of the pathogenic PINK1 p.Q456X substitution. Both patients presented with dystonia and gait disorders at symptom onset. Seven heterozygous mutation carriers remained unaffected. Functional studies revealed that the PINK1 p.Q456X protein is non-functional in activating the downstream ubiquitin ligase parkin and priming the ubiquitination of its substrates, and that the RNA levels of PINK1 were significantly reduced. CONCLUSIONS: The PINK1 p.Q456X mutation leads to a decrease in mRNA and a loss of protein function. The foot dystonia and gait disorders seen at disease onset in affected members of our family, which were accompanied by parkinsonism had a similar clinical presentation to what has been described in previous reports of PINK1 mutation carriers.
BACKGROUND: Recessive mutations in the PTEN-induced putative kinase 1 (PINK1) gene cause early-onset Parkinson's disease (EOPD). The clinical phenotype of families that have this PINK1-associated disease may present with different symptoms, including typical PD. The loss of the PINK1 protein may lead to mitochondrial dysfunction, which causes dopaminergic neuron death. METHODS: The clinical phenotypes of a large Polish family with EOPD and an identified PINK1 homozygous nonsense mutation were assessed. Ubiquitination and degradation of mitochondrial parkin substrates as well as mitochondrial bioenergetics were investigated as direct functional readouts for PINK1's kinase activity in biopsied dermal fibroblasts. RESULTS: A four-generation family was genealogically evaluated. Genetic screening identified two affected subjects who were both homozygous carriers of the pathogenic PINK1p.Q456X substitution. Both patients presented with dystonia and gait disorders at symptom onset. Seven heterozygous mutation carriers remained unaffected. Functional studies revealed that the PINK1p.Q456X protein is non-functional in activating the downstream ubiquitin ligase parkin and priming the ubiquitination of its substrates, and that the RNA levels of PINK1 were significantly reduced. CONCLUSIONS: The PINK1p.Q456X mutation leads to a decrease in mRNA and a loss of protein function. The foot dystonia and gait disorders seen at disease onset in affected members of our family, which were accompanied by parkinsonism had a similar clinical presentation to what has been described in previous reports of PINK1 mutation carriers.
Authors: L Ishihara-Paul; M M Hulihan; J Kachergus; R Upmanyu; L Warren; R Amouri; R Elango; R K Prinjha; A Soto; M Kefi; M Zouari; S B Sassi; S B Yahmed; G El Euch-Fayeche; P M Matthews; L T Middleton; R A Gibson; F Hentati; M J Farrer Journal: Neurology Date: 2008-08-06 Impact factor: 9.910
Authors: Cindy Zadikoff; Ekaterina Rogaeva; Ana Djarmati; Christine Sato; Shabnam Salehi-Rad; Peter St George-Hyslop; Christine Klein; Anthony E Lang Journal: Mov Disord Date: 2006-06 Impact factor: 10.338
Authors: Kenya Nishioka; Mounir Kefi; Barbara Jasinska-Myga; Christian Wider; Carles Vilariño-Güell; Owen A Ross; Michael G Heckman; Lefkos T Middleton; Lianna Ishihara-Paul; Rachel A Gibson; Rim Amouri; Samia Ben Yahmed; Samia Ben Sassi; Mourad Zouari; Ghada El Euch; Matthew J Farrer; Faycal Hentati Journal: J Neurol Neurosurg Psychiatry Date: 2009-09-02 Impact factor: 10.154
Authors: V Bonifati; C F Rohé; G J Breedveld; E Fabrizio; M De Mari; C Tassorelli; A Tavella; R Marconi; D J Nicholl; H F Chien; E Fincati; G Abbruzzese; P Marini; A De Gaetano; M W Horstink; J A Maat-Kievit; C Sampaio; A Antonini; F Stocchi; P Montagna; V Toni; M Guidi; A Dalla Libera; M Tinazzi; F De Pandis; G Fabbrini; S Goldwurm; A de Klein; E Barbosa; L Lopiano; E Martignoni; P Lamberti; N Vanacore; G Meco; B A Oostra Journal: Neurology Date: 2005-07-12 Impact factor: 9.910
Authors: Andrey Yurevich Abramov; Matthew Gegg; Anne Grunewald; Nicholas William Wood; Christine Klein; Anthony Henry Vernon Schapira Journal: PLoS One Date: 2011-10-17 Impact factor: 3.240
Authors: Oliver Cooper; Hyemyung Seo; Shaida Andrabi; Cristina Guardia-Laguarta; John Graziotto; Maria Sundberg; Jesse R McLean; Luis Carrillo-Reid; Zhong Xie; Teresia Osborn; Gunnar Hargus; Michela Deleidi; Tristan Lawson; Helle Bogetofte; Eduardo Perez-Torres; Lorraine Clark; Carol Moskowitz; Joseph Mazzulli; Li Chen; Laura Volpicelli-Daley; Norma Romero; Houbo Jiang; Ryan J Uitti; Zhigao Huang; Grzegorz Opala; Leslie A Scarffe; Valina L Dawson; Christine Klein; Jian Feng; Owen A Ross; John Q Trojanowski; Virginia M-Y Lee; Karen Marder; D James Surmeier; Zbigniew K Wszolek; Serge Przedborski; Dimitri Krainc; Ted M Dawson; Ole Isacson Journal: Sci Transl Med Date: 2012-07-04 Impact factor: 19.319
Authors: Fabienne C Fiesel; Maya Ando; Roman Hudec; Anneliese R Hill; Monica Castanedes-Casey; Thomas R Caulfield; Elisabeth L Moussaud-Lamodière; Jeannette N Stankowski; Peter O Bauer; Oswaldo Lorenzo-Betancor; Isidre Ferrer; José M Arbelo; Joanna Siuda; Li Chen; Valina L Dawson; Ted M Dawson; Zbigniew K Wszolek; Owen A Ross; Dennis W Dickson; Wolfdieter Springer Journal: EMBO Rep Date: 2015-07-10 Impact factor: 8.807
Authors: Rafiqua Ben El Haj; Wafaa Regragui; Rachid Tazi-Ahnini; Asmae Skalli; Naima Bouslam; Ali Benomar; Mohamed Yahyaoui; Ahmed Bouhouche Journal: Biomed Res Int Date: 2016-06-20 Impact factor: 3.411
Authors: Maya Ando; Fabienne C Fiesel; Roman Hudec; Thomas R Caulfield; Kotaro Ogaki; Paulina Górka-Skoczylas; Dariusz Koziorowski; Andrzej Friedman; Li Chen; Valina L Dawson; Ted M Dawson; Guojun Bu; Owen A Ross; Zbigniew K Wszolek; Wolfdieter Springer Journal: Mol Neurodegener Date: 2017-04-24 Impact factor: 14.195